Use of ent-allopregnanolone to treat glaucoma

Tech ID: T-018940

Technology Description

Researchers from Washington University in St. Louis and colleagues have identified ent-allopregnanolone (ent-AlloP) as a potential therapeutic to treat glaucoma. Glaucoma, the leading cause of irreversible blindness, results from damage to the retinal ganglion cells (RGSs) that form the optic nerve. Increased intraocular pressure can damage RGCs and is a major risk factor for glaucoma. However, the pathogenesis underlying RGC damage by intraocular pressure elevation remains unclear. Although the damage caused by glaucoma cannot be reversed, glaucoma can be treated by lowering the intraocular pressure to slow or prevent further damage. Having additional therapeutics with new mechanisms of action to treat glaucoma would be beneficial. To help meet this need, the inventors have identified ent-AlloP, the enantiomeric form of allopregnanolone (AlloP), as a potential new therapeutic to treat glaucoma. They have found that both AlloP and ent-AlloP are neuroprotective but ent-AlloP acts through a different mechanism to prevent loss of RGCs caused by glaucoma. This technology provides a new therapeutic for the treatment of glaucoma.

Stage of Research

The inventors have found that AlloP and ent-AlloP are neuroprotective in both ex vivo and in vivo rat models of ocular hypertension but they operate through distinct mechanisms.

Applications

  • Therapeutic for glaucoma

Key Advantages

  • Novel therapeutic for glaucoma
  • Different mechanism of action than existing therapeutics

Publications

Patents

  • Provisional patent application has been filed

Related Web Links

Create a Collection
Creating...